External broker reports(aggregated public sources), HDFC Securities

HDFC Securities

External broker reports(aggregated public sources)

HDFC securities is the best online trading platform for stocks, IPOs, mutual fund in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Event-Driven

Sun Pharmaceutical Industries / Event-Driven

<ul>
<li>Sun Pharma (SUNP) and Checkpoint Therapeutics Inc (Checkpoint) have entered into an agreement under which SUNP will acquire Checkpoint, an immunotherapy and targeted oncology company</li>
<li>SUNP will pay a total consideration of ~USD 355 mn (~USD 4.1 per share) as upfront cash, plus an additional USD 0.7 per share as a non-transferable contingent value right upon achieving certain approval milestones in the European Union</li>
<li>This will add Unloxcyt (Cosibelimab-ipdl), an anti-PD-L1 treatment approved for cutaneous squamous cell carcinoma (cSCC), to SUNP’s global onco-derm franchise, along with other pipeline products (four molecules under development for non-small cell lung cancer and solid tumour indications)</li>
</ul>
<p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>


Sun Pharma (SUNP) and Checkpoint Therapeutics Inc (Checkpoint) have entered into an agreement under which SUNP will acquire Checkpoint, an immunotherapy and targeted oncology company
SUNP will pay a total consideration of ~USD 355 mn (~USD 4.1 per share) as upfront cash, plus an additional USD 0.7 per share as a non-transferable contingent value right upon achieving certain approval milestones in the European Union
This will add Unloxcyt (Cosibelimab-ipdl), an anti-PD-L1 treatment approved for cutaneous squamous cell carcinoma (cSCC), to SUNP’s global onco-derm franchise, along with other pipeline products (four molecules under development for non-small cell lung cancer and solid tumour indications)

Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Sun Pharmaceutical Industries: Checkpoint Acquisition to Strengthen Specialty Business.

United States

Checkpoint Therapeutics, Inc. operates as a biopharmaceutical company. The Company focuses on the acquisition, development, and commercialization of immune-enhanced combination treatments for patients with solid tumor cancers. Checkpoint Therapeutics serves patients in the United States.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Checkpoint Therapeutics (CKPT US)

Sun Pharmaceutical Industries: Checkpoint Acquisition to Strengthen Specialty Business.

Sun Pharma (SUNP) and Checkpoint Therapeutics Inc (Checkpoint) have entered into an agreement under which SUNP will acquire Checkpoint, an...

HDFC Securities

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)